In the following video, Motley Fool health-care analyst David Williamson discusses some very surprising trial results from Amgen (AMGN 1.71%). The company has announced phase 3 results that it has bioengineered a version of the herpes virus to attack melanoma, by singling out only fast-dividing cells. David tells us the possible ramifications both for investors and for patients.
Why Melanoma Should Fear Herpes
By Dave Williamson – Mar 20, 2013 at 7:30PM
NASDAQ: AMGN
Amgen
Market Cap
$159B
Today's Change
(-1.71%) $5.16
Current Price
$295.98
Price as of October 22, 2025 at 4:00 PM ET
Amgen hunts cancer with a modified herpes virus.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid